Literature DB >> 16098278

Predictors of pharmacotherapy response in anxiety disorders.

Damiaan Denys1, Femke de Geus.   

Abstract

Although treatment with different compounds such as tricyclic antidepressants, selective serotonin reuptake inhibitors, high-potency benzodiazepines, and monoamine oxidase inhibitors has been proven effective in anxiety disorders, 20% to 40% of patients are nonresponders. Given the limited efficacy, the delayed onset of response (it takes several weeks before a clinical effect can be seen for most of these drugs), and the occurrence of side effects associated with pharmacotherapy, predicting response in anxiety disorders would be immensely valuable. This review surveys the literature over the past years on predictors of response to pharmacotherapy in obsessive-compulsive disorder, social anxiety disorder, panic disorder, and posttraumatic stress disorder. Prediction of treatment response may be founded on demographic and clinical variables, neurochemical and electrophysiologic parameters, imaging studies, and genetic markers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098278     DOI: 10.1007/s11920-005-0078-4

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  63 in total

1.  Heart rate variability as predictor of nonresponse to mirtazapine in panic disorder: a preliminary study.

Authors:  B R Slaap; M L Boshuisen; A M van Roon; J A den Boer
Journal:  Int Clin Psychopharmacol       Date:  2002-03       Impact factor: 1.659

2.  The effect of pharmacotherapist characteristics on treatment outcome in panic disorder.

Authors:  Jack M Gorman; José M Martinez; Raymond Goetz; Jonathan D Huppert; Susan Ray; David H Barlow; M Katherine Shear; Scott W Woods
Journal:  Depress Anxiety       Date:  2003       Impact factor: 6.505

3.  Fluoxetine versus placebo in posttraumatic stress disorder.

Authors:  Ferenc Martenyi; Eileen B Brown; Harry Zhang; Apurva Prakash; Stephanie C Koke
Journal:  J Clin Psychiatry       Date:  2002-03       Impact factor: 4.384

4.  Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression.

Authors:  Sanjaya Saxena; Arthur L Brody; Matthew L Ho; Narineh Zohrabi; Karron M Maidment; Lewis R Baxter
Journal:  Am J Psychiatry       Date:  2003-03       Impact factor: 18.112

5.  Pharmacotherapy and regional cerebral blood flow in children with obsessive compulsive disorder.

Authors:  Rasim Somer Diler; Mustafa Kibar; Ayse Avci
Journal:  Yonsei Med J       Date:  2004-02-29       Impact factor: 2.759

6.  The association between panic disorder and the L/L genotype of catechol-O-methyltransferase.

Authors:  Jong-Min Woo; Kyung-Sik Yoon; Young-Hee Choi; Kang-Sub Oh; Young-Sik Lee; Bum-Hee Yu
Journal:  J Psychiatr Res       Date:  2004 Jul-Aug       Impact factor: 4.791

7.  Personality disorder and social anxiety predict delayed response in drug and behavioral treatment of panic disorder.

Authors:  Peter Berger; Gabriele Sachs; Michaela Amering; Anita Holzinger; Bettina Bankier; Heinz Katschnig
Journal:  J Affect Disord       Date:  2004-05       Impact factor: 4.839

8.  Overvalued ideation as a predictor of fluvoxamine response in patients with obsessive-compulsive disorder.

Authors:  Fugen Neziroglu; Anthony Pinto; Jose A Yaryura-Tobias; Dean McKay
Journal:  Psychiatry Res       Date:  2004-01-30       Impact factor: 3.222

9.  Tranylcypromine in social phobia.

Authors:  M Versiani; F D Mundim; A E Nardi; M R Liebowitz
Journal:  J Clin Psychopharmacol       Date:  1988-08       Impact factor: 3.153

10.  Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder.

Authors:  Jeffrey L Berlant
Journal:  BMC Psychiatry       Date:  2004-08-18       Impact factor: 3.630

View more
  7 in total

1.  Bumetanide blocks the acquisition of conditioned fear in adult rats.

Authors:  Meng-Chang Ko; Ming-Chung Lee; Tso-Hao Tang; Tamara G Amstislavskaya; Maria A Tikhonova; Yi-Ling Yang; Kwok-Tung Lu
Journal:  Br J Pharmacol       Date:  2018-04-16       Impact factor: 8.739

2.  A positron emission tomography study of the serotonergic system in relation to anxiety in depression.

Authors:  Zafer Iscan; Gopalkumar Rakesh; Samantha Rossano; Jie Yang; Mengru Zhang; Jeffrey Miller; Gregory M Sullivan; Priya Sharma; Matthew McClure; Maria A Oquendo; J John Mann; Ramin V Parsey; Christine DeLorenzo
Journal:  Eur Neuropsychopharmacol       Date:  2017-08-12       Impact factor: 4.600

Review 3.  Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD.

Authors:  Benjamin D Greenberg; Scott L Rauch; Suzanne N Haber
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 4.  Pharmacogenetics of anxiolytic drugs.

Authors:  Arun K Tiwari; Renan P Souza; Daniel J Müller
Journal:  J Neural Transm (Vienna)       Date:  2009-05-12       Impact factor: 3.575

Review 5.  Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety.

Authors:  R E Nordquist; T Steckler; J G Wettstein; C Mackie; W Spooren
Journal:  Psychopharmacology (Berl)       Date:  2008-03-06       Impact factor: 4.530

6.  A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.

Authors:  Andrew D Krystal; Diego A Pizzagalli; Moria Smoski; Sanjay J Mathew; John Nurnberger; Sarah H Lisanby; Dan Iosifescu; James W Murrough; Hongqiu Yang; Richard D Weiner; Joseph R Calabrese; Gerard Sanacora; Gretchen Hermes; Richard S E Keefe; Allen Song; Wayne Goodman; Steven T Szabo; Alexis E Whitton; Keming Gao; William Z Potter
Journal:  Nat Med       Date:  2020-03-30       Impact factor: 53.440

7.  Loop diuretics have anxiolytic effects in rat models of conditioned anxiety.

Authors:  Andrew D Krystal; Janice Sutherland; Daryl W Hochman
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.